| Generic name | Midostaurin |
| Pronunciation | MY-doh-STAW-rin |
| Brand name(s), other common name(s) | Rydapt® |
| Drug type | Kinase inhibitor |
| How the drug is given | By mouth |
Indications and Usage
Rydapt is FDA approved for the treatment of adult patients with:
- Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
Limitations of Use:
RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. - Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Side effects needing medical attention
- AML: The most common adverse reactions were a fever in a patient with neutropenia, nausea, mucositis, vomiting, headache, petechiae, musculoskeletal pain, nose bleed, device-related infection, hyperglycemia (high blood sugar), and upper respiratory tract infection.
- ASM, SM-AHN, or MCL: The most common adverse reactions were nausea, vomiting, diarrhea, edema, musculoskeletal pain, abdominal pain, fatigue, upper respiratory tract infection, constipation, fever, headache, and difficulty breathing.
Warning: Monitor for symptoms of interstitial lung disease or pneumonitis. Discontinue Rydapt in patients with signs or symptoms of pulmonary toxicity.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.